The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s acute myeloid leukemia market report forecasts the acute myeloid leukemia market size to grow to $2.03 Billion by 2027, with a CAGR (compound annual growth rate) of 12%.

Learn More On The Acute Myeloid Leukemia Market Report 2023 – https://www.thebusinessresearchcompany.com/report/acute-myeloid-leukemia-global-market-report

Acute Myeloid Leukemia Market Size Forecast
The global acute myeloid leukemia market is expected to grow from $1.15 billion in 2022 to $1.29 billion in 2023 at a compound annual growth rate (CAGR) of 12.38%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The acute myeloid leukemia market size is expected to grow to $2.03 billion in 2027 at a CAGR of 12.03%.

North America held the largest acute myeloid leukemia market share.

Key Acute Myeloid Leukemia Market Driver ­– Increase In The Older Population Base And Growing Unmet Healthcare Needs
For instance, according to the American Cancer Society USA (ACS), a nationwide voluntary health organization, in 2022, AML was commonly found in elderly people with an average age at diagnosis being 68, and survival of elderly AML patients remained remarkably low. It affected approximately 60,650 people in 2022 and caused 24000 deaths.. Therefore, the geriatric population base and growing unmet healthcare needs drive the gelatin market.

Request for A Sample Of The Global Acute Myeloid Leukemia Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6100&type=smp

Key Acute Myeloid Leukemia Market Trend – Growing Investments In R&D
Growing investments in R&D using the pharmaceutical groups are a key trend gaining popularity in the acute myeloid leukemia market. R&D is used to develop new and improved products and services to fulfill the needs of drug development. For instance, in April 2020, the Poland based biopharmaceutical company, Ryvu partnered with Italian pharmaceutical company, Menarini and completed the Phase I part of the Phase I/II trial in acute myeloid leukemia (AML) and presented the first-ever data with an in-house developed asset.

Acute Myeloid Leukemia Market Segment
1) By Treatment Type: Chemotherapy, Radiation therapy, Stem Cell Transplant, Targeted Therapy
2) By Chemotherapy: Cytarabine, Anthracycline Drugs, Alkylating Agents, Anti-metabolites, Tyrosine Kinase Inhibitors, Hormonal Therapy
3) By Regimen: DC Regimen, AVD Regimen, VCD Regimen
4) By End-User: Hospital, Retails Drug Stores, Ambulatory Care Centers, Clinics

Acute Myeloid Leukemia Market Major Players and Strategies
Major players in the acute myeloid leukemia market are Pfizer Inc., Novartis AG, Sanofi-Aventis (Genzyme Corporation), Bristol Myers Squibb, Amgen Inc., Celgene Corporation, and Ambit Biosciences Corporation, Takeda Pharmaceuticals.

In March 2020, Gilead Sciences, Inc an American biopharmaceutical company acquired Forty-Seven, Inc. for $95.50 per share in cash which values Forty-Seven at approximately $4.9 billion. The acquisition will strengthen Gilead’s immuno-oncology research and development portfolio due to the addition of Forty Seven’s investigational lead product candidate, Magrolimab. Magnolia is a monoclonal antibody in clinical development for the treatment of several cancers for which new, transformative medicines are urgently needed, including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and diffuse large B-cell lymphoma (DLBCL). Forty-Seven is a US based clinical-stage immuno-oncology company focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer.

The Acute Myeloid Leukemia Global Market Report 2023 covers regional data on acute myeloid leukemia market size, acute myeloid leukemia market trends and drivers, opportunities, strategies, and acute myeloid leukemia market competitor analysis. The countries covered in the acute myeloid leukemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Acute myeloid leukemia (AML) is a type of blood cancer that occurs due to abnormal white blood cell in bone marrow. Myeloblasts, also known as leukaemic blasts, or excessive production of immature white blood cells, are the hallmark of AML. The bone marrow is crowded with these cells, which stops it from producing healthy blood cells.

View More Reports Related To The Acute Myeloid Leukemia Market –
Leukemia Therapeutics Global Market Report 2023
Lung Cancer Drugs Global Market Report 2023
Pain Management Devices And Therapies Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: